GlassScriptPhysician profile
Laura M Ledlie
NPI 1871576447
$1,282.29
in general payments reported to CMS, 2019-2025
25 companies · $476 in 2025
The $476 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $106 · 2023: $123 · 2024: $368 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $195.03 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $190.07 | 2019-2024 | Jornay Pm |
| Alk-Abello, INC | $126.92 | 2023-2025 | Grastek, Odactra, Neffy |
| Genzyme Corporation | $114.40 | 2025 | |
| Pfizer INC. | $107.80 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $62.09 | 2019-2025 | Rotateq, Gardasil 9, Vaxneuvance |
| Tris Pharma INC | $59.09 | 2019 | |
| Cranial Technologies, INC | $58.87 | 2024 | Doc Band |
| Masimo Corporation | $50.61 | 2020 | |
| Collegium Pharmaceutical, INC. | $36.53 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $29.04 | 2024 | Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $25.88 | 2019-2020 | |
| Soleno Therapeutics, INC. | $24.69 | 2025 | Vykat Xr |
| Biomarin Pharmaceutical INC. | $22.92 | 2024 | Voxzogo 1.2mg |
| Phadia US INC. | $21.34 | 2025 | Immunocap |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $20.72 | 2024 | |
| Genentech USA, INC. | $17.61 | 2020 | |
| Azurity Pharmaceuticals, INC. | $17.32 | 2025 | Alvesco |
| Glaxosmithkline, LLC. | $16.01 | 2025 | Penmenvy |
| Supernus Pharmaceuticals, INC. | $15.91 | 2024 | Qelbree |
| Aytu Biopharma, INC. | $14.81 | 2025 | |
| Organon LLC | $14.05 | 2025 | |
| Mission Pharmacal Company | $13.82 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.62 | 2019 | |
| Shire North American Group INC | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Ledlie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.